Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elanco Animal Health Incorporated (NYSE: ELAN) SEC filings page on Stock Titan provides organized access to the company’s U.S. regulatory disclosures. As an Indiana-incorporated public company in the pharmaceutical preparation manufacturing industry, Elanco files reports with the Securities and Exchange Commission under Commission File Number 001-38661.
Through this page, readers can review current and historical Forms 8-K and, when available, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials. Elanco’s recent Form 8-K filings illustrate the range of topics covered in its SEC disclosures, including quarterly financial results and guidance, restructuring plans and workforce changes, amendments to credit agreements and receivables facilities, and participation in major investor events such as its Investor Day and healthcare conferences.
These filings provide detail on Elanco’s financial condition, capital structure and risk factors, as well as material contracts and strategic initiatives. For example, recent 8-Ks describe the Elanco Ascend restructuring program, expected cost savings, facility changes, and refinancing of term loan facilities, along with updates on leverage targets and cash flow expectations. Other filings outline amendments to securitization and credit agreements that affect the company’s direct financial obligations.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the significance of each filing. Investors can use the ELAN filings page to monitor new 8-Ks, as well as future 10-K and 10-Q reports, and to track how management’s strategic, financial and operational decisions are reflected in official SEC documents.
Elanco Animal Health Inc: Dimensional Fund Advisors filed an amended Schedule 13G/A reporting beneficial ownership of 24,527,135 shares of Elanco common stock, equal to 4.9% of the class. The filing shows sole voting power for 24,146,632 shares and was signed on 04/09/2026.
Elanco Animal Health is asking shareholders to elect five directors, ratify Ernst & Young as auditor, and approve an advisory vote on executive pay at its virtual 2026 annual meeting. The company highlights 2025 results of $4.715 billion revenue, $901 million adjusted EBITDA and $0.94 adjusted EPS, with 7% organic constant currency revenue growth and 10 consecutive quarters of underlying growth.
Innovation delivered $892 million of revenue in 2025, and Elanco targets about $1.15 billion of innovation revenue in 2026 plus 5–6 potential blockbuster approvals between 2026 and 2031. Net leverage was 3.6x in 2025, with a goal of less than 3x in 2027, supported by the Elanco Ascend productivity program, which is expected to provide $200–$250 million of adjusted EBITDA savings by 2030.
The proxy stresses governance changes, including a phased declassification of the Board by 2027, majority voting in uncontested director elections, proxy access, and shareholder rights to amend bylaws and call special meetings. Executive compensation remains heavily performance-based, with 2025 annual incentives paying at 109% of target and performance shares at 106% of target, and 2026 plans adding a relative total shareholder return metric and a sales growth modifier.
Elanco Animal Health Inc executive Rajeev A. Modi received a grant of deferred stock units as part of his compensation. On this award date, he acquired 64.7209 deferred stock units tied to Company common stock at a reference value of $22.82 per unit.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after his employment ends or in a specified future year under the Company’s Executive Deferral and Stock Match Plan. Following this grant, Modi holds a total of 9,137.6387 deferred stock units directly.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc President and CEO Jeffrey N. Simmons received a grant of 123.8795 deferred stock units on Company common stock. These units were valued at $22.82 per unit on the grant date and increase his directly held deferred stock unit balance to 23,919.1498 units.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. The units will settle in cash or shares following Simmons’ termination of employment or in a specified future year under the Company’s Executive Deferral and Stock Match Plan, making this a routine, compensation-related award rather than an open-market purchase.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.6337 deferred stock units on Company common stock, valued at $22.82 per unit. After this award, he holds a total of 57.4266 deferred stock units directly. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent and will settle in cash or shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.
Elanco Animal Health officer Ellen de Brabander reported equity compensation activity in the company’s common stock. On April 1, 2026, she received a grant of 40,985 shares, recorded at no purchase price. On the same date, 20,288 shares were disposed of at $23.12 per share to satisfy tax obligations, a tax-withholding transaction rather than an open-market sale. Following these entries, she directly holds 280,821 shares of Elanco common stock.
Anand Kapila K reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc director K. Anand received an automatic grant of 600.7104 Deferred Stock Units as part of her director compensation. These units reflect cash retainer fees she chose to defer under the Company’s Directors' Deferral Plan, using a grant-date Elanco common stock price of $23.93.
Each Deferred Stock Unit is economically equivalent to one share of Elanco common stock and will be settled in stock when she separates from the Board. Following this award, she holds a total of 9,495.4518 Deferred Stock Units directly.
Elanco Animal Health Inc amendment: The Vanguard Group filed a Schedule 13G/A reporting 0 shares of Elanco common stock. The filing states that Vanguard completed an internal realignment on January 12, 2026, after which certain subsidiaries report beneficial ownership separately. The form is signed by Ashley Grim on 03/26/2026.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health reported that President and CEO Jeffrey N. Simmons received a grant of 117.887 deferred stock units on 2026-03-20. Each unit represents the right to receive one share of Elanco common stock or the cash equivalent. Following this grant, Simmons directly holds a total of 23,795.2703 deferred stock units, which will settle in cash or shares after his employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health executive Rajeev A. Modi received a grant of 61.5901 deferred stock units tied to common stock. These units are part of an Executive Deferral and Stock Match Plan and will settle in cash or shares after employment ends or in a specified future year. Following this award, Modi holds 9,072.9178 deferred stock units.